. intolerance). Ibrutinib is the current gold standard therapy for people with relapsed/refractory condition, according to the results of several period I-III trials, 115–119 but This is often also shifting for two most important good reasons: (i) an ever-increasing proportion of people now get ibrutinib as frontline therapy; and (ii) some signif